Sam Tejada, CEO and Founder of Liquivida®, sits down with Dr. Adeel Khan for a wide-ranging conversation on regenerative medicine, the biology of aging, stem cell exhaustion, inflammation, proteomics, artificial intelligence, and where personalized healthcare could be heading next.
On this episode of “A Healthy Point of View” podcast, the discussion goes beyond the usual advice about eating well, exercising, and getting enough sleep. Those things still matter, but Dr. Khan looks at a different question: what is actually happening inside the body as we age, and how much of it can we understand, measure, or potentially change?
The conversation also touches on something that has become increasingly difficult to ignore. Longevity is growing quickly, but the quality of information and treatments available to people varies considerably.
Dr. Khan describes the current longevity space as something of a “Wild, Wild West,” with many different therapies being offered without a clear understanding of what works, for whom, and under what circumstances. He points to Dubai’s planned Dubai Longevity Authority as one possible step toward putting safeguards around some of the more experimental treatments entering the field.
For him, better regulation and better measurement need to develop alongside the treatments themselves.
Stem Cells, Proteomics & AI: Are We About to Rewrite Aging? Dr. Adeel Khan | Ep. 173
Aging Starts With What Happens Inside the Cell
There are 12 widely discussed hallmarks of aging, but Dr. Khan does not view all of them as equally important.
His approach is to look for the things that sit further upstream. If one process contributes to several other problems, understanding that process could potentially tell us more than looking at each problem separately.
One of the areas he focuses on is mitochondrial dysfunction.
Mitochondria are often described as the batteries of our cells. As they become less efficient, they can contribute to oxidative stress and damage involving cellular membranes and DNA. Over time, the information that tells cells what to do can also become less reliable.
Dr. Khan connects this to epigenetic drift. In simple terms, cells can lose some of the clarity around their identity and function.
That leads to an interesting question: if cells lose information as they age, could some of that information be restored?
That is where the idea of epigenetic reprogramming enters the conversation.
Can Aging Cells Be Reprogrammed?
Dr. Khan explains that some of the excitement around cellular reprogramming came from research by Professor Shinya Yamanaka, whose work demonstrated that mature cells could be reprogrammed into a stem-cell-like state.
The discovery was a major moment in biology. It showed that a cell’s identity was not necessarily as permanent as scientists once thought.
But Dr. Khan is also careful about the gap between an exciting scientific discovery and something that can safely be translated into everyday medicine.
There was enormous enthusiasm around the possibilities of cellular reprogramming, but clinical translation is much harder than proving something can happen in a laboratory or animal model.
That distinction matters throughout the longevity field.
Dr. Khan discusses research involving signals such as exosomes, stem cells, secretomes, and Yamanaka-related factors, including OSK. These areas are generating considerable interest, but much of the work remains experimental.
For now, he sees exercise, strength, VO2 max, grip strength, and sleep as important parts of the foundation. The more advanced regenerative approaches should not be viewed as replacements for those basics.
Regenerative Medicine Is Not Just About Joints
Exosomes and stem cells are often discussed in the context of injuries and joint problems. Dr. Khan sees a much broader area of investigation.
The conversation explores whether regenerative signals could eventually have applications beyond treating a specific damaged area, including systemic approaches related to aging and biological repair.
But this is also where quality becomes important.
Dr. Khan raises concerns about the variation between products in the regenerative medicine market and the need for stronger independent testing and verification. A therapy can sound impressive on paper, but that does not automatically tell you what is actually inside a particular product or whether it will produce the desired result.
He also discusses autoimmune patients and why the order in which someone approaches treatment matters.
In his view, regenerative therapies should not necessarily be the first step for everyone. Someone dealing with complex immune dysfunction may need to address foundational issues first. Gut health, hormones, functional genomics, and other biological factors can provide important context before moving toward more advanced interventions.
There is no single treatment that makes sense for every person.
That idea comes up repeatedly throughout the discussion.
Why Proteomics Could Change the Way We Understand the Body
One of the most detailed parts of the conversation centers on proteomics.
The basic idea is fairly straightforward. DNA gives us information about the blueprint, but proteins are doing much of the actual work inside the body. Looking at proteins can therefore provide a different picture of what is happening biologically at a particular point in time.
Dr. Khan compares it to looking under the hood of a car.
Some conventional measurements can tell you something about the exhaust coming out of the system. Proteomics, in his analogy, gives you a chance to look more closely at the engine itself.
That distinction becomes especially useful when trying to understand complicated problems.
Take cortisol as an example. A person might have a high morning cortisol reading, but that number alone does not necessarily explain why it is high. Dr. Khan explains that several different mechanisms could potentially be involved.
Proteomic data can look at proteins associated with those different pathways and provide a much more detailed picture.
The same idea applies to sleep.
Rather than simply saying someone has poor sleep and recommending that they try a particular supplement or routine, proteomic information could potentially reveal biological pathways associated with inflammation, oxidative stress, cortisol regulation, vascular function, or metabolism.
That does not mean proteomics can instantly solve every health problem. It means the measurement itself can become more informative.
For Dr. Khan, that is what makes it exciting.
Where AI Comes Into the Picture
There is one obvious problem with collecting thousands of biological measurements: humans are not particularly good at manually processing that amount of information.
A physician can interpret a substantial number of biomarkers, but the amount of data produced by modern multi-omics testing can become far more complicated.
This is where artificial intelligence enters the discussion.
Dr. Khan describes the possibility of using biological AI to interpret complex proteomic signatures and identify patterns that would be difficult for a person to process manually.
That leads to another concept Sam asks him to explain: the digital twin.
A digital twin, as Dr. Khan describes it, would essentially be a detailed digital model of an individual based on information collected through different biological measurement technologies.
In theory, that model could eventually be used to explore how someone might respond to different interventions. Information from the real world could then be added back into the model over time.
The result would not simply be a single test taken once a year.
It would be an evolving picture of the individual.
Dr. Khan believes this type of technology could become one of the most important developments in personalized longevity medicine over the next five years. As more information is collected through proteomics, lipidomics, RNA sequencing, genomics, and other technologies, the potential for increasingly personalized recommendations grows.
It is an ambitious vision, and much of it remains ahead of where medicine is today.
Start With the Basics
For all the discussion about advanced technology, Dr. Khan repeatedly comes back to the fundamentals.
Personalized medicine does not begin with the most expensive or experimental therapy available. It starts with understanding the individual, establishing a strong foundation, and then deciding what additional interventions actually make sense.
That can include lifestyle, exercise, sleep, nutrition, and personalized supplementation. Genomics can provide information about what someone may be predisposed to, while proteomics can offer a view of what is happening more immediately.
The combination is where Dr. Khan sees the real potential.
He also points out that some of the most talked-about longevity treatments, including peptides, still do not have the depth of human clinical trial evidence that people sometimes assume they do.
That is an important reminder in a field where marketing can move considerably faster than science.
Longevity Is About More Than Biology
Toward the end of the conversation, Sam asks Dr. Khan a more personal question: what might he regret most when he looks back on his life?
His answer is not about missing a particular medical breakthrough or career achievement.
He talks about relationships and the possibility of not keeping in touch with friends.
It is a small moment in a conversation filled with discussions about cells, biomarkers, AI, and regenerative medicine, but it puts the subject of longevity into a different perspective.
Living longer is not necessarily the same thing as living better.
Dr. Khan also explains that his interest in integrative medicine was not originally driven by celebrity patients or the attention that eventually came with his work. It began with wanting to help his mother and other family members dealing with chronic health problems and questioning whether medication was always the only answer.
That curiosity eventually became a much broader interest in finding better ways to understand the body.
Looking Under the Hood
The future described during this episode is still being built.
Some technologies are established. Others are early-stage research. Some ideas may eventually become important parts of medicine, while others may not translate into useful treatments at all.
That uncertainty is precisely why measurement, regulation, and good evidence matter.
Dr. Khan’s central idea is that the body has an intricate communication system, and aging can disrupt that communication. The hope behind regenerative medicine is that the right signals and tools might one day help restore some of what has been lost.
AI and technologies such as proteomics could make it possible to understand that system in far greater detail than before.
For Sam and Dr. Khan, that is the exciting part of where healthcare could be headed: moving beyond simply asking whether someone is healthy or unhealthy and starting to understand what is happening underneath the surface.
Sometimes, the most useful place to begin is simply to look under the hood.